References

1. Murphy MP, LeVine H (2010) Alzheimer’s Disease and the β-Amyloid Peptide. J Alzheimers Dis. 2010 Jan; 19: 311 [CrossRef] [PubMed]
2. Jack CR Jr, Knopman DS, Jagust WJ, Petersen RC, Weiner MW, et al. (2013) Update on hypothetical model of Alzheimer’s disease biomarkers, Lancet Neurol. 12: 207-216 [CrossRef] [Google Scholar] [PubMed]
3. Tarasoff-Conway JM, Carare RO, Osorio RS, Glodzik L, Butler T, et al. (2015) Clearance systems in the brain-implications for Alzheimer disease, Nat Rev Neurol. 11: 457-470 [CrossRef] [Google Scholar] [PubMed]
4. Alzheimer's Association (2011) Brain Tour
5. Buchhave P, Minthon L, Zetterberg H, Wallin AK, Blennow K, et al. (2012) Cerebrospinal Fluid Levels of β-Amyloid 1-42, but Not of Tau, Are Fully Changed Already 5 to 10 Years Before the Onset of Alzheimer Dementia. Arch Gen Psychiatry 69: 98-106 [CrossRef] [Google Scholar] [PubMed]
6. New Medical Life Sciences (2014) What are Tau Proteins?
7. Braak H, Del Tredici K (2011) The pathological process underlying Alzheimer’s disease in individuals under thirty. Acta Neuropathol 121: 171- 181 [CrossRef] [Google Scholar] [PubMed]
8. Streit WJ, Mrak RE, Griffin WS (2004) Microglia and neuroinflammation: a pathological perspective, Journal of Neuroinflammation 1: 14 [CrossRef] [Google Scholar] [PubMed]
9. Stevens B Lab, FM Kirby Neurobiology Center, Research Associate in Neurology, Children's Hospital and Harvard Medical School, Boston, Massachusetts
10. Eurekalert, Global Source for Science News (2017) Higher brain glucose levels may mean more severe Alzheimer's, Press Release [View]
11. Li JJ, Dolios G, Wang R, Liao FF (2014) Soluble Beta-Amyloid Peptides, but Not Insoluble Fibrils, Have Specific Effects on Neuronal MicroRNA Expression, PLoS One 9: e90770 [CrossRef] [Google Scholar] [PubMed]